Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity
Ophthalmology 2023;130:373-378 ª 2022 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmolog
This study compares the retreatments between Bevacizumab and Ranibizumab intravitreal injections in treating Retinopathy of Prematurity (ROP), examining if specific dosages or types of anti-vascular endothelial growth factors (VEGF) are associated with retreatment. Data from 873 eyes of 661 patients were collected. The primary analysis included 567 eyes of 307 patients, where no significant difference was found between the no retreatment and retreatment groups in terms of birthweight, gestational age, age at first injection, ROP stages, or number of involved clock hours. However, the retreatment group had a larger percentage of aggressive ROP (34% vs 18%) and a greater percentage of zone 1 ROP (49% vs 34%). Concurrently, lower doses of Bevacizumab were associated with higher retreatment rates. The results also found that the use of Ranibizumab was associated with a higher rate of retreatment, whereas the rate of retreatment was not associated with a specific dose of ranibizumab. In a multicenter study of ROP patients initially treated with anti-VEGF therapy, ranibizumab and
lower-dose bevacizumab use were associated with an increased rate of retreatment when compared with higher dose bevacizumab.